Scholarlink

Aim <p>To evaluate lymphoid enhancer-binding factor 1 (LEF1) as an immunohistochemical marker for WNT-activated medulloblastoma (WNT-MB).</p> Materials and methods <p>Medulloblastomas (MB) diagnosed between January 2022 and April 2024, that were molecularly grouped by gene expression profiling and in which LEF1 immunohistochemistry was available formed the study cohort.</p> Results <p>A of total 151 cases, comprising 40 (26.49%) WNT-activated, 45 (29.80%) SHH-activated, and 66 (43.71%) non-WNT/non-SHH (group 3: 21, group 4: 34, and NOS, i.e. overlapping between group 3 and group 4: 11)&#xa0;formed the study cohort. Age- range was 1–41&#xa0;years (median: 9&#xa0;years; interquartile- range: 5–17&#xa0;years), 118 (78.15%) patients were ≤ 18&#xa0;years of age, and 33 (21.85%) patients had &gt; 18&#xa0;years age. LEF1 immunostaining was diffuse (≥ 50% tumour cells) in 32 cases, focal (1–49% tumour cells) in 11 cases, and negative in 108 cases. Diffuse LEF1 staining was observed only in WNT-MB. Focal LEF1 staining was observed in 20% (8/40) of WNT-MB and 6.67% (3/45) of SHH-activated MBs. All 66 non-WNT/non-SHH MB were negative for LEF1. Diffuse (&gt; 50%) LEF1 immunostaining had 100% positive predictive value, 100% specificity and 80% sensitivity for detecting WNT-MB.</p> Conclusion <p>Diffuse LEF1 immunostaining is a reliable and faster method for identifying WNT-activated molecular group of&#xa0;MB.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月17日

查看全文
  • Manali Ranade,
  • Sridhar Epari,
  • Mamta Gurav,
  • Ayushi Sahay,
  • Prakash Shetty,
  • Maya Prasad,
  • Tejpal Gupta,
  • Girish Chinnaswamy

摘要

Aim

To evaluate lymphoid enhancer-binding factor 1 (LEF1) as an immunohistochemical marker for WNT-activated medulloblastoma (WNT-MB).

Materials and methods

Medulloblastomas (MB) diagnosed between January 2022 and April 2024, that were molecularly grouped by gene expression profiling and in which LEF1 immunohistochemistry was available formed the study cohort.

Results

A of total 151 cases, comprising 40 (26.49%) WNT-activated, 45 (29.80%) SHH-activated, and 66 (43.71%) non-WNT/non-SHH (group 3: 21, group 4: 34, and NOS, i.e. overlapping between group 3 and group 4: 11) formed the study cohort. Age- range was 1–41 years (median: 9 years; interquartile- range: 5–17 years), 118 (78.15%) patients were ≤ 18 years of age, and 33 (21.85%) patients had > 18 years age. LEF1 immunostaining was diffuse (≥ 50% tumour cells) in 32 cases, focal (1–49% tumour cells) in 11 cases, and negative in 108 cases. Diffuse LEF1 staining was observed only in WNT-MB. Focal LEF1 staining was observed in 20% (8/40) of WNT-MB and 6.67% (3/45) of SHH-activated MBs. All 66 non-WNT/non-SHH MB were negative for LEF1. Diffuse (> 50%) LEF1 immunostaining had 100% positive predictive value, 100% specificity and 80% sensitivity for detecting WNT-MB.

Conclusion

Diffuse LEF1 immunostaining is a reliable and faster method for identifying WNT-activated molecular group of MB.